Background: NR2F1-AS1 is a long non-coding RNA (lnc RNA) that is involved in different biological processes. It plays an integral role in the pathophysiology of human diseases, especially tumorigenesis and progression. Therefore, it may be a promising target for numerous tumor biotherapeutics. The current review study aimed to show the pathophysiological activities and processes of RNA NR2F1-AS1 in cancer cells.
Methods: The contents of the present review were based on information obtained from PubMed. In the data search, “NR2F1-AS1” was chosen as the first keyword, whereas “cancer” was chosen as the second keyword. This review selected and summarized studies published between 2019-2021, concerning the biological functions and mechanisms of NR2F1-AS1 in the development of tumorigenesis.
Results: It was found that NR2F1-AS1 regulates a variety of biological activities such as proliferation, invasion, migration, and apoptosis. It acts as an oncogene because it is abnormally expressed and promotes the progression of cancer in a variety of malignancies, including esophageal squamous cell carcinoma, non-small cell lung cancer, breast cancer, neuroblastoma, endometrial cancer, thyroid cancer, and gastric cancer. However, it was evident that NR2F1-AS1 inhibits the progression of cancer in cervical squamous cell carcinoma.
Conclusion: NR2F1-AS1 is a potential new biomarker and therapeutic target for the treatment of different cancers.
[http://dx.doi.org/10.1016/j.ccell.2015.02.004] [PMID: 25759022]
[http://dx.doi.org/10.1084/jem.20210836] [PMID: 34812843]
[http://dx.doi.org/10.15252/embj.2019104163] [PMID: 32484994]
[http://dx.doi.org/10.1038/ncomms7170] [PMID: 25636082]
[http://dx.doi.org/10.1016/j.bbrc.2019.09.015] [PMID: 31530388]
[http://dx.doi.org/10.26355/eurrev_202012_24174] [PMID: 33378023]
[http://dx.doi.org/10.1080/21655979.2021.2001168] [PMID: 34738863]
[http://dx.doi.org/10.3389/fcell.2021.688949] [PMID: 34746118]
[http://dx.doi.org/10.1002/ijc.29210] [PMID: 25220842]
[http://dx.doi.org/10.1146/annurev-med-061512-105739] [PMID: 24274180]
[http://dx.doi.org/10.1038/onc.2012.76] [PMID: 22430211]
[http://dx.doi.org/10.1007/s12029-020-00572-z] [PMID: 33411259]